October 2020 Vol 11, No 10

Did you attend our virtual Midyear Conference in May? It was an incredible event! At first, the thought of switching our usual in-person conference to a virtual one was a bit disappointing to me. But there were several elements of that experience that made the virtual conference one of my all-time favorites.
The authors report results from their prospective study of the effect of a patient navigation program on distress and health-related quality of life.
Osimertinib in the adjuvant treatment setting significantly improves disease-free survival (DFS) in patients with localized non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation.
A strong screening program can make a big difference. Here are tips for your program from the Maine Lung Cancer Coalition.
For some patients, the use of CAR-T cell therapy has resulted in robust and durable (>95%) responses lasting longer than 5 years. Here’s what you need to know about CAR T-cell therapy.
What you need to know about lessening the burden of a metastatic diagnosis.
Fertility preservation is a time-sensitive and logistic-heavy process. Are you having the right conversations with your patients?
With a follow-up of >5 years, women with relapsed platinum-sensitive ovarian cancer and a BRCA mutation who participated in the multicenter phase 3 SOLO2 trial lived >1 year longer if randomized to maintenance olaparib compared with placebo, according to data released at the ASCO20 Virtual Scientific Program.
Learn how to assess and recognize distress in your patients – and what you can do about it.
Presenting the concept of the tumor board to your patient and acting as their representative.
There’s a new standard of care in the first-line setting for a subset of patients with advanced colorectal cancer.

Results 1 - 11 of 11

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State